THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS

被引：0
|
作者：
Nowak, R.
Benatar, M.
Ciafaloni, E.
Howard, J.
Leite, M.
Utsugisawa, K.
Vissing, J.
Wu, Y.
Abuhatzira, L.
Katz, E.
Ratchford, J.
机构：
来源：
MUSCLE & NERVE | 2020年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [31] Mycophenolate mofetil for myasthenia gravis - A double-blind, placebo-controlled pilot study
    Meriggioli, MN
    Rowin, J
    Richman, JG
    Leurgans, S
    MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOMCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 : 494 - 499
  • [32] CORRELATION BETWEEN MYASTHENIA GRAVIS-ACTIVITIES OF DAILY LIVING (MG-ADL) AND QUANTITATIVE MYASTHENIA GRAVIS (QMG) ASSESSMENTS OF ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE REFRACTORY GENERALIZED MYASTHENIA GRAVIS IN THE PHASE 3 REGAIN STUDY
    Vissing, John
    O'Brien, Fanny
    Wang, Jing Jing
    Howard, James F., Jr.
    MUSCLE & NERVE, 2018, 58 (02) : E21 - E22
  • [33] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
    Howard, James F. Jr Jr
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Perk, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    LANCET NEUROLOGY, 2021, 20 (07): : 526 - 536
  • [34] PHASE 3 TRIAL INVESTIGATING IMPACT OF INTRAVENOUS EFGARTIGIMOD IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY NEGATIVE GENERALIZED MYASTHENIA GRAVIS
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 538 - 538
  • [35] Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
    Jared
    Guptill, Jeffrey
    Jimenez, Rosa H.
    Howard, James F., Jr.
    ANNALS OF NEUROLOGY, 2024, 96 : S270 - S271
  • [36] A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis
    Strijbos, Ellen
    Tannemaat, Martijn R.
    Alleman, Iris
    de Meel, Robert H. P.
    Bakker, Jaap A.
    van Beek, Ruud
    Kroon, Frank P.
    Rimmelzwaan, Guus F.
    Verschuuren, Jan J. G. M.
    VACCINE, 2019, 37 (07) : 919 - 925
  • [37] ECULIZUMAB SAFETY AND EFFICACY IN REFRACTORY MYASTHENIA GRAVIS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY
    Howard, J.
    Utsugisawa, K.
    Beneatr, M.
    Murai, H.
    Barohn, R.
    Sendra, I. I.
    Pons, C. C.
    Jacob, S.
    Cutter, Gary
    Vissing, J.
    Burns, T.
    Bleecker, J. D.
    Kissel, J.
    Muppidi, S.
    Nowak, R.
    O'Brien, F.
    Wang, J.
    Vu, T.
    Mantegazza, R.
    MUSCLE & NERVE, 2016, 54 (03) : 645 - 645
  • [38] The Effect of CD3-Specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis
    Ruonan Xu~1 Jianan Wang~1 Guojiang Chen~1 Gencheng Han~1 Renxi Wang~1 Beifen Shen~1 Yan Li~(1
    ~2Department of Molecular Immunology
    Cellular & Molecular Immunology, 2005, (06) : 461 - 465
  • [39] The Effect of CD3-Specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis
    Xu, Ruonan
    Wang, Jianan
    Chen, Guojiang
    Han, Gencheng
    Wang, Renxi
    Shen, Beifen
    Li, Yan
    CELLULAR & MOLECULAR IMMUNOLOGY, 2005, 2 (06) : 461 - 465
  • [40] Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study
    Nowak, Richard J.
    Coffey, Christopher S.
    Goldstein, Jonathan M.
    Dimachkie, Mazen M.
    Benatar, Michael
    Kissel, John T.
    Wolfe, Gil, I
    Burns, Ted M.
    Freimer, Miriam L.
    Nations, Sharon
    Granit, Volkan
    Smith, A. Gordon
    Richman, David P.
    Ciafaloni, Emma
    Al-Lozi, Muhammad T.
    Sams, Laura Ann
    Quan, Dianna
    Ubogu, Eroboghene
    Pearson, Brenda
    Sharma, Aditi
    Yankey, Jon W.
    Uribe, Liz
    Shy, Michael
    Amato, Anthony A.
    Conwit, Robin
    O'Connor, Kevin C.
    Hafler, David A.
    Cudkowicz, Merit E.
    Barohn, Richard J.
    NEUROLOGY, 2022, 98 (04) : E376 - E389
12345